March 6, 2017 / 8:48 AM / a year ago

BRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories

March 6 (Reuters) - Theratechnologies Inc

* Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies

* Theratechnologies acquires commercial rights to Ibalizumab in the european union and four additional territories

* Theratechnologies-Existing agreement between both companies has been amended to include additional territories and related new obligations

* Theratechnologies inc -reached agreement with Taimed Biologics,for acquisition of commercial rights to Ibalizumab in European Union, Israel, Norway, Russia and Switzerland

* Says under terms of agreement, Theratechnologies will assume regulatory responsibilities and associated costs

* Theratechnologies inc - both parties have agreed to a transfer price of 52% for annual European sales up to us$50m

* Says transfer price will increase to 57% on annual sales above us$50m threshold Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below